Chase C. Leavitt - Net Worth and Insider Trading
Chase C. Leavitt Net Worth
The estimated net worth of Chase C. Leavitt is at least $13,637 dollars as of 2024-09-20. Chase C. Leavitt is the General Counsel/Secretary of Oncternal Therapeutics Inc and owns about 5,345 shares of Oncternal Therapeutics Inc (ONCT) stock worth over $9,087. Chase C. Leavitt is also the General Counsel/Secretary of Lineage Cell Therapeutics Inc and owns about 5,000 shares of Lineage Cell Therapeutics Inc (LCTX) stock worth over $4,550. Details can be seen in Chase C. Leavitt's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Chase C. Leavitt has not made any transactions after 2023-04-13 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Chase C. Leavitt
Chase C. Leavitt Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Chase C. Leavitt owns 2 companies in total, including Lineage Cell Therapeutics Inc (LCTX) , and Oncternal Therapeutics Inc (ONCT) .
Click here to see the complete history of Chase C. Leavitt’s form 4 insider trades.
Insider Ownership Summary of Chase C. Leavitt
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| LCTX | Lineage Cell Therapeutics Inc | 2019-08-13 | General Counsel/Secretary |
| ONCT | Oncternal Therapeutics Inc | 2023-04-13 | General Counsel/Secretary |
Chase C. Leavitt Latest Holdings Summary
Chase C. Leavitt currently owns a total of 2 stocks. Among these stocks, Chase C. Leavitt owns 5,345 shares of Oncternal Therapeutics Inc (ONCT) as of April 13, 2023, with a value of $9,087 and a weighting of 66.63%. Chase C. Leavitt also owns 5,000 shares of Lineage Cell Therapeutics Inc (LCTX) as of August 13, 2019, with a value of $4,550 and a weighting of 33.37%.
Latest Holdings of Chase C. Leavitt
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ONCT | Oncternal Therapeutics Inc | 2023-04-13 | 5,345 | 1.70 | 9,087 |
| LCTX | Lineage Cell Therapeutics Inc | 2019-08-13 | 5,000 | 0.91 | 4,550 |
Holding Weightings of Chase C. Leavitt
Chase C. Leavitt Form 4 Trading Tracker
According to the SEC Form 4 filings, Chase C. Leavitt has made a total of 3 transactions in Oncternal Therapeutics Inc (ONCT) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in Oncternal Therapeutics Inc is the acquisition of 1,250 shares on April 13, 2023, which cost Chase C. Leavitt around $7,250.
According to the SEC Form 4 filings, Chase C. Leavitt has made a total of 0 transactions in Lineage Cell Therapeutics Inc (LCTX) over the past 5 years. The most-recent trade in Lineage Cell Therapeutics Inc is the acquisition of 5,000 shares on August 13, 2019, which cost Chase C. Leavitt around $5,100.
Insider Trading History of Chase C. Leavitt
- 1
Chase C. Leavitt Trading Performance
GuruFocus tracks the stock performance after each of Chase C. Leavitt's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Chase C. Leavitt is -6.09%. GuruFocus also compares Chase C. Leavitt's trading performance to market benchmark return within the same time period. The performance of stocks bought by Chase C. Leavitt within 3 months outperforms 1 times out of 4 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Chase C. Leavitt's insider trading performs compared to the benchmark.
Performance of Chase C. Leavitt
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -3.46 | | | | | |
| Relative Return to S&P 500(%) | -3.8 | | | | | |
Chase C. Leavitt Ownership Network
Chase C. Leavitt Owned Company Details
What does Lineage Cell Therapeutics Inc do?
Who are the key executives at Lineage Cell Therapeutics Inc?
Chase C. Leavitt is the General Counsel/Secretary of Lineage Cell Therapeutics Inc. Other key executives at Lineage Cell Therapeutics Inc include Chief Financial Officer Jill Ann Howe , director & President and CEO Brian M Culley , and 10 percent owner Broadwood Partners Lp .
Lineage Cell Therapeutics Inc (LCTX) Insider Trades Summary
Over the past 18 months, Chase C. Leavitt made no insider transaction in Lineage Cell Therapeutics Inc (LCTX). Other recent insider transactions involving Lineage Cell Therapeutics Inc (LCTX) include a net purchase of 6,730,770 shares made by Broadwood Partners Lp , a net purchase of 96,155 shares made by Don M Bailey , and a net purchase of 10,500 shares made by Jill Ann Howe .
In summary, during the past 3 months, insiders sold 0 shares of Lineage Cell Therapeutics Inc (LCTX) in total and bought 10,500 shares, with a net purchase of 10,500 shares. During the past 18 months, 0 shares of Lineage Cell Therapeutics Inc (LCTX) were sold and 6,857,425 shares were bought by its insiders, resulting in a net purchase of 6,857,425 shares.
Lineage Cell Therapeutics Inc (LCTX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Lineage Cell Therapeutics Inc Insider Transactions
Chase C. Leavitt Mailing Address
Above is the net worth, insider trading, and ownership report for Chase C. Leavitt. You might contact Chase C. Leavitt via mailing address: 1010 Atlantic Avenue, Suite 102, Alameda Ca 94501.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
